Exosome nanovesicles displaying G protein-coupled receptors for drug discovery

od Estelles, Angeles, Sperinde, Jeff, Roulon, Thibaut, Aguilar, Barbara, Bonner, Caroline, LePecq, Jean-Bernard, Delcayre, Alain
Wydane 2007

Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer

od Montemurro, Filippo, Prat, Aleix, Rossi, Valentina, Valabrega, Giorgio, Sperinde, Jeff, Peraldo-Neia, Caterina, Donadio, Michela, Galván, Patricia, Sapino, Anna, Aglietta, Massimo, Baselga, José, Scaltriti, Maurizio
Wydane w Mol Oncol (2013)

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant

od Growdon, Whitfield B., Groeneweg, Jolijn, Byron, Virginia, DiGloria, Celeste, Borger, Darrell R., Tambouret, Rosemary, Foster, Rosemary, Chenna, Ahmed, Sperinde, Jeff, Winslow, John, Rueda, Bo R.
Wydane w Gynecol Oncol (2015)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

od Toi, Masakazu, Sperinde, Jeff, Huang, Weidong, Saji, Shigehira, Winslow, John, Jin, Xueguang, Tan, Yuping, Ohno, Shinji, Nakamura, Seigo, Iwata, Hiroji, Masuda, Norikazu, Aogi, Kenjiro, Morita, Satoshi, Petropoulos, Christos, Bates, Michael
Wydane 2010

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

od Chumsri, Saranya, Sperinde, Jeff, Liu, Heshan, Gligorov, Joseph, Spano, Jean-Philippe, Antoine, Martine, Aspitia, Alvaro Moreno, Tan, Winston, Winslow, John, Petropoulos, Christos J, Chenna, Ahmed, Bates, Michael, Weidler, Jodi Marie, Huang, Weidong, Dueck, Amylou, Perez, Edith A.
Wydane w Clin Cancer Res (2018)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

od Duchnowska, Renata, Sperinde, Jeff, Czartoryska-Arłukowicz, Bogumiła, Myśliwiec, Paulina, Winslow, John, Radecka, Barbara, Petropoulos, Christos, Demlova, Regina, Orlikowska, Marlena, Kowalczyk, Anna, Lang, Istvan, Ziółkowska, Barbara, Dębska-Szmich, Sylwia, Merdalska, Monika, Grela-Wojewoda, Aleksandra, Żawrocki, Anton, Biernat, Wojciech, Huang, Weidong, Jassem, Jacek
Wydane w Oncotarget (2017)

Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2(+) Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy

od Duchnowska, Renata, Biernat, Wojciech, Szostakiewicz, Barbara, Sperinde, Jeff, Piette, Fanny, Haddad, Mojgan, Paquet, Agnes, Lie, Yolanda, Czartoryska-Arłukowicz, Bogumiła, Wysocki, Piotr, Jankowski, Tomasz, Radecka, Barbara, Foszczyńska-Kłoda, Małgorzata, Litwiniuk, Maria, Dȩbska, Sylwia, Weidler, Jodi, Huang, Weidong, Buyse, Marc, Bates, Michael, Jassem, Jacek
Wydane 2012

Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy

od Duchnowska, Renata, Biernat, Wojciech, Szostakiewicz, Barbara, Sperinde, Jeff, Piette, Fanny, Haddad, Mojgan, Paquet, Agnes, Lie, Yolanda, Czartoryska-Arłukowicz, Bogumiła, Wysocki, Piotr, Jankowski, Tomasz, Radecka, Barbara, Foszczynska-Kloda, Malgorzata, Litwiniuk, Maria, Dȩbska, Sylwia, Weidler, Jodi, Huang, Weidong, Buyse, Marc, Bates, Michael, Jassem, Jacek
Wydane 2013

Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases

od Duchnowska, Renata, Sperinde, Jeff, Chenna, Ahmed, Huang, Weidong, Weidler, Jodi M., Winslow, John, Haddad, Mojgan, Paquet, Agnes, Lie, Yolanda, Trojanowski, Tomasz, Mandat, Tomasz, Kowalczyk, Anna, Czartoryska-Arłukowicz, Bogumiła, Radecka, Barbara, Jarosz, Bożena, Staszkiewicz, Rafal, Kalinka-Warzocha, Ewa, Chudzik, Małgorzata, Biernat, Wojciech, Jassem, Jacek
Wydane w Neuro Oncol (2015)

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

od Ghosh, Ritwik, Narasanna, Archana, Wang, Shizhen Emily, Liu, Shuying, Chakrabarty, Anindita, Balko, Justin M., González-Angulo, Ana María, Mills, Gordon B., Penuel, Elicia, Winslow, John, Sperinde, Jeff, Dua, Rajiv, Pidaparthi, Sailaja, Mukherjee, Ali, Leitzel, Kim, Kostler, Wolfgang J., Lipton, Allan, Bates, Michael, Arteaga, Carlos L.
Wydane 2011

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with...

od Yardley, Denise A, Kaufman, Peter A, Huang, Weidong, Krekow, Lea, Savin, Michael, Lawler, William E, Zrada, Stephen, Starr, Alexander, Einhorn, Harvey, Schwartzberg, Lee S, Adams, John W, Lie, Yolanda, Paquet, Agnes C, Sperinde, Jeff, Haddad, Mojgan, Anderson, Steve, Brigino, Marlon, Pesano, Rick, Bates, Michael P, Weidler, Jodi, Bosserman, Linda
Wydane w Breast Cancer Res (2015)

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

od Abraham, Jame, Montero, Albert J., Jankowitz, Rachel C., Salkeni, Mohamad Adham, Beumer, Jan H., Kiesel, Brian F., Piette, Fanny, Adamson, Laura M., Nagy, Rebecca J., Lanman, Richard B., Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J., Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L., Lucas, Peter C., Jacobs, Samuel A.
Wydane w J Clin Oncol (2019)

Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

od Mamluk, Roni, Carvajal, Irvith M, Morse, Brent A, Wong, Henry, Abramowitz, Janette, Aslanian, Sharon, Lim, Ai-Ching, Gokemeijer, Jochem, Storek, Michael J, Lee, Joonsoo, Gosselin, Michael, Wright, Martin C, Camphausen, Ray T, Wang, Jack, Chen, Yan, Miller, Kathy, Sanders, Kerry, Short, Sarah, Sperinde, Jeff, prasad, Gargi, Williams, Stephen, Kerbel, Robert, ebos, John, Mutsaers, Anthony, Mendlein, John D, Harris, Alan S, Furfine, Eric S
Wydane 2010

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

od Lipton, Allan, Goodman, Laurie, Leitzel, Kim, Cook, Jennifer, Sperinde, Jeff, Haddad, Mojgan, Köstler, Wolfgang J., Huang, Weidong, Weidler, Jodi M., Ali, Suhail, Newton, Alicia, Fuchs, Eva-Marie, Paquet, Agnes, Singer, Christian F., Horvat, Reinhard, Jin, Xueguang, Banerjee, Joyee, Mukherjee, Ali, Tan, Yuping, Shi, Yining, Chenna, Ahmed, Larson, Jeff, Lie, Yolanda, Sherwood, Thomas, Petropoulos, Christos J., Williams, Stephen, Winslow, John, Parry, Gordon, Bates, Michael
Wydane 2013

p95HER2–T cell bispecific antibody for breast cancer treatment

od Ruiz, Irene Rius, Vicario, Rocio, Morancho, Beatriz, Morales, Cristina Bernadó, Arenas, Enrique J., Herter, Sylvia, Freimoser-Grundschober, Anne, Somandin, Jitka, Sam, Johannes, Ast, Oliver, Barriocanal, Águeda Martinez, Luque, Antonio, Escorihuela, Marta, Varela, Ismael, Cuartas, Isabel, Nuciforo, Paolo, Fasani, Roberta, Peg, Vicente, Rubio, Isabel, Cortés, Javier, Serra, Violeta, Escriva-de-Romani, Santiago, Sperinde, Jeff, Chenna, Ahmed, Huang, Weidong, Winslow, John, Albanell, Joan, Seoane, Joan, Scaltriti, Maurizio, Baselga, Jose, Tabernero, Josep, Umana, Pablo, Bacac, Marina, Saura, Cristina, Klein, Christian, Arribas, Joaquín
Wydane w Sci Transl Med (2018)